natgillin/translations-raw huggingface dataset:
Risikoen for torsades de pointes er relateret til sværhedsgraden af QT-forlængelsen, samtidig indgift af QT-forlængende lægemidler, torsades de pointes i anamnesen, allerede eksisterende QT-intervalforlængelse, kongestiv hjertestop, indgift af kaliumsænkende diuretika, eller andre konditioner, som resulterer i hypokaliæmi eller hypomagnesiæmi.
The risk of torsade de pointes is related to the extent of QT prolongation, concomitant administration of QT prolonging medicinal products, a history of torsade de pointes, preexisting QT interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalaemia or hypomagnesaemia.
Risikoen for trombocytopeni pga. heparin kan vare ved i adskillige år.
The risk of thrombocytopenia due to the use of heparin may persist for several years.
Risikoen for tromboemboliske tilfælde var størst i de første fire måneder af behandlingen.
The risk of a thromboembolic event was greatest in the first four months of therapy.
Risikoen for udvikling af cancer i disse studier var den samme i de grupper, der fik raltegravir og de grupper, der fik sammenligningspræparater.
The risk of developing cancer in these studies was similar in the groups receiving raltegravir and in the groups receiving comparators.
Risikoen for udvikling af cancer i disse studier var den samme i de grupper, som fik ISENTRESS og i de grupper, der fik sammenligningspræparater.
The risk of developing cancer in these studies was similar in the groups receiving ISENTRESS and in the groups receiving comparators.
Risikoen for udvikling af resistens over for delamanid ser ud til at være forhøjet, når det anvendes sammen med nogle få midler, der forudses at være aktive og/eller når disse yderligere midler ikke var blandt dem, der anses for mest effektive over for M. tuberculosis.
The risk of selecting for resistance to delamanid appears to be increased when it is used with few agents predicted to be active and/or when these additional agents were not among those deemed to be most effective against M. tuberculosis.
Risikoen for udvikling af YMDD- mutation var 63 % versus 13 % ved cut offværdi på 1.000 kopier/ml (NUCB3009 og NUCB3018).
The risk for developing YMDD mutant was 63% versus 13% with a cut off of 1000 copies/ml (NUCB3009 and NUCB3018).
Risikoen for udvikling af YMDD-mutation var 63 % versus 13 % ved cut off- værdi på 1.000 kopier/ml (NUCB3009 og NUCB3018).
The risk for developing YMDD mutant was 63% versus 13% with a cut off of 1000 copies/ml (NUCB3009 and NUCB3018).
Risikoen for venetrombose vedvarer i 4−6 uger efter ophør med p-piller af kombinationstypen.
The risk of venous thromboembolism continues for 4−6 weeks after discontinuing combined oral contraception.
Risikoen for venøs tromboemboli vedvarer i 4-6 uger efter ophør med orale kombinationspræparater.
The risk of venous thromboembolism continues for 4−6 weeks after discontinuing combined oral contraception.
Risikoen for vertikal viral transmission ved spredning af virus er teoretisk ubetydelig, men kan dog ikke udelukkes.
The risk on virus shedding vertical viral transmission is theoretically negligible however not excluded.
Risikoen for VTE (dyb venetrombose og lungeemboli) er øget for andre selektive østrogenreceptormodulatorer (SERM'er).
The risk of VTE (deep vein thrombosis and pulmonary embolism) is increased with other selective oestrogen receptor modulators (SERMs).
Risikoen for øget mortalitet hos patienter med hjerte-lunge-sygdomme
The risk of increased mortality in patients with cardiopulmonary diseases
Risikoen for øget systemisk toksicitet bør tages i betragtning ved administration af store doser af Fortacin til patienter, der i forvejen bruger andre lokalanæstetika eller strukturelt beslægtede lægemidler, f.eks. klasse I-antiarytmika såsom mexiletin.
The risk of additional systemic toxicity should be considered when large doses of Fortacin are applied to patients already using other local anaesthetics or structurally related medicinal products e.g. class I anti-arrhythmics such as mexiletine.
Risikoen for, at De får knogleproblemer er større, hvis De:
The risk of you having bone problems is higher if you:
Risikoen for, at kapslen går i stykker, er større, hvis kapslen gennembores mere end én gang i trin 6.
The chances of the capsule breaking into pieces are increased if the capsule is pierced more than once during Step 6.
Risikoen for, at kapslen splintres, er større, hvis kapslen ved et uheld perforeres mere end én gang, eller hvis inhalatoren ikke holdes, så mundstykket vender nedad under trin 7.
The chances of the capsule breaking into pieces will be increased if the capsule is accidentally pierced more than once or if the device is not held with the mouthpiece pointing down during step 7.
Risikoen for, at kapslen splintres, forøges, hvis kapslen perforeres mere end en enkelt gang (trin 7).
The chances of the capsule shattering will be increased if the capsule is pierced more than once (step 7).
Risikoen for, at Vistide og anti-HIV-proteasehæmmere påvirker hinanden, er ikke blevet undersøgt.
The potential for interactions between Vistide and anti-HIV protease inhibitors has not been studied.
Risikoen forbliver indtil, der er signifikant remission.
This risk persists until significant remission occurs.
Risikoen forbundet med olanzapin var i studiet sammenlignelig med risikoen forbundet med de atypiske antipsykotika, som var inkluderet i en pooled analyse
In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.
Risikoen forbundet med ukorrekt opbevaring og ukorrekt håndtering
The risks associated with incorrect storage and mishandling
Risikoen fortsætter dog ud over denne periode, og overvågning med hyppige intervaller bør fortsættes under behandlingen.
However the risk continues past this period and monitoring should continue at frequent intervals throughout treatment.
Risikoen kan øges, hvis behandlingen kombineres med andre lægemidler, der også kan fremprovokere hyperkaliæmi (kaliumholdige salterstatninger, kaliumbesparende diuretika, ACE-hæmmere, angiotensin II-receptorantagonister, nonsteroide antiinflammatoriske lægemidler (NSAIDere herunder selektive COX-2-hæmmere), heparin, immunosuppressiva (ciclosporin eller tacrolimus) og trimethoprim).
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti- inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Risikoen kan øges, når dalkoncentration af sirolimus stiger.
The risk may increase as the trough sirolimus level increases.
Risikoen ser ud til at være højere, når fibrinvævsklæbere sprayes med luft i modsætning til CO2, og det kan derfor ikke udelukkes med Raplixa.
The risk appears to be higher when fibrin sealants are sprayed with air, as compared to CO2 and therefore cannot be excluded with Raplixa.
Risikoen stiger væsentligt i takt med, at BMI stiger.
Risk increases substantially as BMI rises.
Risikoen synes at være højere, når fibrinklæbere sprøjtes med luft end med CO2, og dette kan derfor ikke udelukkes med Raplixa.
The risk appears to be higher when fibrin sealants are sprayed with air, as compared to CO2 and therefore cannot be excluded with Raplixa.
risikoen ved behandling med eculizumab
the risks of treatment with eculizumab
Risikoen ved off label-brug ved medfødt FXIII-mangel
The risks of off-label use within FXIII congenital deficiency
Risikoen ved, at gravide kvinder tager Suboxone, er ukendt.
The risks of using Suboxone in pregnant women are not known.
risikoen, skal samtidig
of bedaquiline with
risikoen, skal samtidig administration
If the benefit outweighs
Risikoestimat for HIV 1- Beskyttelse:
Risk Estimate for HIV-1 Protection:
risikofaktorer for
or risk factors for
risikofaktorer for
or risk factors for seizures were reported11
Risikofaktorer for at udvikle akut snævervinklet glaukom kan omfatte allergi over for sulfonamider eller antibiotika i anamnesen.
Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy.
Risikofaktorer for en kardiel bivirkning blev identificeret i fire store adjuverende studier og inkluderede alder (> 50 år), lav LVEF (< 55 %) ved baseline før eller efter initiering af paclitaxel- behandling, fald i LVEF på 10-15 point samt tidligere eller samtidig brug af antihypertensiva.
Risk factors for a cardiac event identified in four large adjuvant studies included advanced age (> 50 years), low LVEF (<55%) at baseline, prior to or following the initiation of paclitaxel treatment, decline in LVEF by 10-15 points, and prior or concurrent use of anti-hypertensive medicinal products.
Risikofaktorer for en kardiel bivirkning blev identificeret i fire store adjuverende studier og inkluderede alder (> 50 år), lav LVEF (< 55 %) ved baseline før eller efterfulgt af initiering af paclitaxel-behandling, fald i LVEF på 10-15 point samt tidligere eller samtidig brug af antihypertensiva.
Risk factors for a cardiac event identified in four large adjuvant studies included advanced age (> 50 years), low LVEF (<55%) at baseline, prior to or following the initiation of paclitaxel treatment, decline in LVEF by 10-15 points, and prior or concurrent use of anti-hypertensive medicinal products.
Risikofaktorer for pneumoni hos patienter med KOL omfatter aktuel rygning, højere alder, lavt BMI og svær KOL.
Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.
Risikofaktorer for TLS inkluderer høj tumorbyrde, præeksisterende kronisk nyreinsufficiens, oliguri, dehydrering, hypotension og sur urin.
Risk factors for TLS include high tumour burden, preexisting chronic renal insufficiency, oliguria, dehydration, hypotension, and acidic urine.
Risikofaktorer for transplantatdelaminering kan omfatte, men er ikke begrænset til, dårlig patient- udvælgelse, utilstrækkelig overholdelse af anbefalet kirurgisk teknik, mangelfuld håndtering af samtidige patologiske tilstande, mangelfuld overholdelse af genoptræningsprotokollen eller postoperativt traume i knæet.
Risk factors for graft delamination can include but are not limited to poor patient selection, poor adherence to recommended surgical technique, failure to address concomitant pathologies, poor compliance with the rehabilitation protocol or post-operative trauma to the knee.
Risikofaktorer for tromboemboliske sygdomme (se nedenfor)
Risk factors for thromboembolic disorders (see below)
Risikofaktorer for udvikling af akut snævervinklet glaukom kan omfatte en forhistorie med sulfonamid- eller penicillinallergi.
Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy.
Risikofaktorer for udvikling af akut snævervinklet glaukom kan være kendt sulfonamid- eller penicillinallergi.
Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy.
Risikofaktorer for udvikling af denne sygdom er blandt mange: Længden af den tidsperiode, hvor du er blevet behandlet med flere antiretrovirale lægemidler, anvendelse af kortikosteroider, alkoholforbrug, alvorligt nedsat immunforsvar samt højt BMI (Body Mass Index).
The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe weakness of the immune system and higher body mass index may be some of the many risk factors for developing this disease.
Risikofaktorer for udvikling af denne sygdom er blandt mange: Længden af den tidsperiode, hvor du er blevet behandlet med flere antiretrovirale lægemidler, anvendelse af kortikosteroider, alkoholforbrug, alvorligt nedsat immunforsvar samt højt BMI (body-mass-index).
The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe weakness of the immune system and higher body mass index may be some of the many risk factors for developing this disease.
Risikofaktorer for udvikling af denne sygdom omfatter: Hvor længe du har fået HIV-medicin, om du får binyrebarkhormon (steroid), hvor meget alkohol du indtager, hvor godt dit immunforsvar er, og om du er overvægtig.
Risk factors for developing this disease include: how long you have been taking anti-HIV medicines, whether you take corticosteroids, how much alcohol you drink, how well your immune system works and being overweight.
Risikofaktorer for østrogenafhængige tumorer, f. eks. arvelig brystcancer i nærmeste familie
Risk factors for oestrogen-dependent tumours, e.g., 1st degree heredity for breast cancer
Risikofaktorer forbundet med udvikling af en rift i pigmentepitelcellelaget i retina efter anti-VEGF- behandling for våd AMD inkluderer en stor/eller høj løsgørelse af det retinale pigmentepitel.
Risk factors associated with the development of a retinal pigment epithelial tear after anti-VEGF therapy for wet AMD, include a large and/or high pigment epithelial retinal detachment.
Risikofaktorer forbundet med udviklingen af en rift i det retinale pigmentepitel efter anti- VEGF-behandling for våd AMD inkluderer en stor og/eller høj løsning af det retinale pigmentepitel.
Risk factors associated with the development of a retinal pigment epithelial tear after anti- VEGF therapy for wet AMD, include a large and/or high pigment epithelial retinal detachment.
Risikofaktorer kan omfatte sygdomme relateret til energimangel, høj kropstilstandsscore og paritet i anamnesen.
Risk factors may include a history of energy-deficiency-related diseases, high body condition score and parity.
Risikofaktorer relateret til ATE, udover underliggende malign sygdom og alder >65 år, omfatter hypertension, diabetes mellitus og tidligere tromboembolisk sygdom.
Risk factors associated with ATE, in addition to the underlying malignant disease and age 65 years, included hypertension, diabetes mellitus, and prior thromboembolic disease.
Risikofaktorer relateret til nedsat nyrefunktion/nyresvigt hos patienter i behandling med sunitinib, udover underliggende renalcellekarcinom, omfatter høj alder, diabetes mellitus, underliggende nedsat nyrefunktion, hjertesvigt, hypertension, sepsis, dehydrering/hypovolæmi og Rabdomyolyse.
Risk factors associated with renal impairment/failure in patients receiving sunitinib included, in addition to underlying renal cell carcinoma, older age, diabetes mellitus, underlying renal impairment, cardiac failure, hypertension, sepsis, dehydration/hypovolemia, and rhabdomyolysis.
Risikofaktorer: I STS fase III-studiet havde tretten af de 15 forsøgspersoner i pazopanib-armen samtidig hypertension, hvilket kan have forværret den kardielle dysfunktion hos disse risikopatienter ved at øge hjertets after-load.
Risk factors: Thirteen of the 15 subjects in the pazopanib arm of the STS phase III study had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk by increasing cardiac after- load.
Risikofaktorerne for pneumoni hos KOL-patienter, der får fluticasonfuroat/vilanterol, omfatter aktiv rygning, pneumoni i anamnesen, BMI < 25 kg/m2 og forceret eksspirationsvolumen (FEV1) < 50 % af den forventede værdi.
Risk factors for pneumonia in patients with COPD receiving fluticasone furoate/vilanterol include current smokers, patients with a history of prior pneumonia, patients with a body mass index <25 kg/m2 and patients with a (forced expiratory volume) FEV1<50% predicted.
Risikofaktorerne for TLS omfatter stor tumorbyrde, høje koncentrationer af cirkulerende celler (25.000/mm3), hypovolæmi, nyreinsufficiens, forhøjet niveau af urinsyre før behandlingen og forhøjet niveau af lactatdehydrogenase.
Risk factors for TLS include a high tumour burden, high concentrations of circulating cells (≥ 25,000/mm3), hypovolaemia, renal insufficiency, elevated pre-treatment uric acid levels and elevated lactate dehydrogenase levels.
Risikofaktorerne for udvikling af inhibitor omfattede i dette studie ikke-kaukasisk etnicitet, tidligere forekomst af inhibitorer i familien og intensiv behandling med høje doser inden for de første 20 eksponeringsdage.
Risk factors related to inhibitor development in this study included non-Caucasian ethnicity, family history of inhibitors and intensive treatment at high dose within the first 20 EDs.
Risikoforhold (95 % C.I.)
Hazard ratio (95% C.I.)
Risikoforhold (95 % CI)
Hazard ratio (95 % C.I.)
Risikoforhold (95 % CI)
Hazard ratio (95 % CI)
Risikoforhold (95 % CI)
Hazard ratio (95% CI)
Risikoforhold (95% CI)
Hazard ratio (95 % CI)
Risikoforhold for overlevelse af intravenøs topotecan i forhold til CAV var 1,04 (95 % CI 0,78; 1,40).
The hazard ratio for survival of IV topotecan relative to CAV was 1.04 (95 % CI 0.78 – 1.40).
Risikoforholdene (HR) for den totale overlevelse var 1,59 (95 % CI for HR = 1,33 - 1,91) med en logrank p < 0,0001 til fordel for TMZ-gruppen.
The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR = 1.33 – 1.91) with a log-rank p < 0.0001 in favour of the TMZ arm.
Risikoforholdene (HR) for den totale overlevelse var 1,59 (95 % CI for HR = 1,33 - 1,91) med en logrank p < 0,0001 til fordel for TMZ-gruppen.
The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR = 1.33 – 91) with a log-rank p < 0.0001 in favour of the TMZ arm.
Risikoforholdet (= hazard ratio) for alle VTE tilfælde i RUTH-studiet var HR = 1,44 (1,06 – 1,95).
The hazard ratio for all VTE events in the RUTH study was HR = 1.44 (1.06 – 1.95).
Risikoforholdet (= hazard ratio) for alle VTE-tilfælde i RUTH-forsøget var
The hazard ratio for all VTE events in the RUTH study was
Risikoforskel (95 % KI)
Risk difference (CI95%)
Risikoforskel vs. warfarin (%)
Risk difference vs. warfarin (%)
Risikoniveau
Risk Level
Risikorate (95 % CI)3
Hazard Ratio (95% CI)3
Risikorate (95% CI)
Hazard ratio (95% CI)
Risikorate [95% CI]
[95% CI]
Risikorate [95% CI] d: 0,73 [0,53; 1,01]
Hazard ratio [95% CI] d: 0.73 [0.53, 1.01]
Risikorate [95% CI] d: 0,78 [0,57; 1,07]
Hazard ratio [95% CI] d: 0.78 [0.57, 1.07]
Risikorate*
0.550
Risikoratio # (RR; 95% CI)
Risk Ratio # (RR; 95% CI)
Risikoratio & 95 % CI
Risk ratio & 95%CI
Risikoratio (95 % CI)
Hazard ratio (95% CI)
Risikoratio (95% CI)b
Hazard ratio b (95% CI)
Risikoratio (97,5 % CI)a
Hazard Ratio (97.5% CI)a
Risikoratio baseret på ikke-stratificeret analyse
Hazard ratio based on non-stratified analysis
Risikoratio#
Risk ratio#
Risikoreduktion for efterfølgende urinsyregigt-anfald målt som tid til først nye udbrud (24 uger)
Risk reduction of subsequent gouty arthritis attacks as measured by time to first new flare (24 weeks)
Risikoreduktionen for sygdoms-progression eller død, som ses hos patienter med indolent non-Hodgkin lymfom, er drevet af undergruppen af patienter med follikulært lymfom.
The reduction in the risk of disease progression or death seen in the iNHL population is driven by the subset of patients with FL.
Risikoreduktionen var konstant på tværs af subgrupper inklusive: køn, alder, race, geografi, NYHA– klasse (II/III), uddrivningsfraktion, nyrefunktion, tidligere diabetes eller hypertension, tidligere behandling for hjertesvigt og hjerteflimmer.
This risk reduction was consistently observed across subgroups including: gender, age, race, geography, NYHA class (II/III), ejection fraction, renal function, history of diabetes or hypertension, prior heart failure therapy, and atrial fibrillation.
Risikorelateret til alogliptin
Risk related to alogliptin
Risikostyringsplan
Risk Management Plan (RMP)
Risikostyringsplan (RMP)
Additional risk minimisation measures
Risikostyringsplan (RMP)
Excipients
Risikostyringsplan (RMP)
Risk Management plan
Risikostyringsplan (RMP)
Risk Management Plan ( RMP)
Risikostyringsplan (RMP)
Risk Management Plan (MRP)
Risikostyringsplan (RMP)
Risk Management Plan(RMP)
Risikostyringsplan (RMP) Ikke relevant
Risk Management Plan (RMP) Not applicable.
Risikostyringsplan (RMP) Ikke relevant.
Risk Management Plan (RMP) Not applicable.
Risikostyringsprogram
Risk Management Plan (RMP)
Risikostyringsprogram (RMP)
Risk Management Plan(RMP)
Risikostyringsprogram (RMP) Ikke relevant.
Risk Management Plan Not Applicable
Risikovurdering og klinisk monitorering er de bedste indikatorer for potentiel blødningsrisiko.
Risk assessment and clinical monitoring are the best indicators of the potential risk of bleeding.
Risikovurdering og klinisk overvågning er de bedste indikatorer for potentiel blødningsrisiko.
Risk assessment and clinical monitoring are the best indicators of the potential risk of bleeding.
Risk ratio = 0,79 (95 % SI 0,53, 1,18)
HR = 0.79 (95% CI 0.53, 1.18)
Risk-benefit-forholdet fremgår af den videnskabelige drøftelse i denne EPAR.
The benefit- risk balance may be found in the scientific discussion module of this EPAR.
Risk/benefit-forholdet fremgår af afsnittet med den videnskabelige drøftelse i denne EPAR.
The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Risokostyringsplan (RMP)
Risk Management Plan (RMP)
Risperidon
Risperidone Thioridazine
Risperidon Thioridazin
Perphenazine Risperidone Thioridazine
Risperidon Thioridazin
Risperidone
Ristaben kan tages med eller uden mad.
Ristaben can be taken with or without food.
Ristaben tilhører en klasse af orale anti-hyperglykæmiske lægemidler, der kaldes dipeptidylpeptidase- 4-(DPP-4)-hæmmere.
Ristaben is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors.
Ristempa 6 mg injektionsvæske, opløsning Pegfilgrastim
Ristempa 6 mg solution for injection Pegfilgrastim
Ristempa er en klar, farveløs injektionsvæske, opløsning i en fyldt injektionssprøjte (6 mg/0,6 ml).
Ristempa is a clear, colourless solution for injection in a pre-filled syringe (6 mg/0.6 ml).
Ristempa gives som en injektion i vævet lige under huden (subkutan injektion).
Ristempa is given as an injection into the tissue just under the skin (subcutaneous injection).
Ristempa inde holder sorbitol (E 420) og natriumacetat
Ristempa contains sorbitol (E420) and sodium acetate
Ristempa injiceres subkutant.
Ristempa is injected subcutaneously.
Ristfor
Strength
Ristfor 50 mg/1.000 mg filmovertrukne tabletter Sitagliptin/metforminhydrochlorid
Ristfor 50 mg/1,000 mg film-coated tablets sitagliptin/metformin hydrochloride
Ristfor 50 mg/850 mg filmovertrukne tabletter sitagliptin/metforminhydrochlorid
Ristfor 50 mg/850 mg film-coated tablets sitagliptin/metformin hydrochloride
Ristfor er en kombination af to antihyperglykæmiske lægemidler med komplementære virkningsmekanismer til forbedring af glykæmisk kontrol hos patienter med type 2-diabetes: Sitagliptinphosphat, en dipeptidylpeptidase-4-hæmmer (DPP-4), og metforminhydrochlorid, der tilhører biguanidklassen.
Ristfor combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Ristfor er indiceret som supplement til diæt og motion til forbedring af den glykæmiske kontrol hos patienter, der ikke er tilstrækkeligt kontrolleret på den maksimalt tolererede dosis metformin alene eller hos de patienter, som allerede er i behandling med en kombination af sitagliptin og metformin.
Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Ristfor er indiceret som tripel kombinationsbehandling sammen med en peroxisom proliferator- aktiveret receptor-gamma (PPAR)-agonist (dvs. et glitazon) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på den maksimalt tolererede dosis metformin og en PPAR-agonist.
Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.